Latus Bio
Latus Bio is dedicated to revolutionizing gene therapy by developing innovative, precision delivery gene therapy candidates using advanced computational methods and unbiased screening. Their mission is to improve patient lives through one-time gene therapies that are potent, specific, safe, and manufacturable, targeting a broad range of CNS and peripheral diseases with a focus on reducing toxicity, costs, and manufacturing requirements.
Industries
Nr. of Employees
small (1-50)
Latus Bio
Products
CLN2 gene therapy candidate (TPP1 replacement via ependyma-targeted capsid)
A one-time gene therapy program designed to deliver functional TPP1 enzyme throughout the CNS using an ependymal-targeting capsid variant to restore lysosomal function in CLN2 disease models.
Huntington's disease gene therapy candidate (MSH3 knockdown)
A one-time gene therapy program aiming to reduce expression of the DNA repair enzyme MSH3 to limit somatic CAG repeat expansion, evaluated in preclinical models with computational predictions of long-term impact.
CLN2 gene therapy candidate (TPP1 replacement via ependyma-targeted capsid)
A one-time gene therapy program designed to deliver functional TPP1 enzyme throughout the CNS using an ependymal-targeting capsid variant to restore lysosomal function in CLN2 disease models.
Huntington's disease gene therapy candidate (MSH3 knockdown)
A one-time gene therapy program aiming to reduce expression of the DNA repair enzyme MSH3 to limit somatic CAG repeat expansion, evaluated in preclinical models with computational predictions of long-term impact.
Services
Collaborative platform combining massively-parallel in vivo screening in non-human primates with computational analysis to identify tissue- and cell-specific capsid variants matched to clinical routes of administration.
End-to-end translational support including preclinical efficacy studies, program management, and clinical operations planning for CNS gene therapy candidates.
Collaborative platform combining massively-parallel in vivo screening in non-human primates with computational analysis to identify tissue- and cell-specific capsid variants matched to clinical routes of administration.
End-to-end translational support including preclinical efficacy studies, program management, and clinical operations planning for CNS gene therapy candidates.
Expertise Areas
- Capsid discovery and engineering
- In vivo high-throughput screening (NHP)
- Translational medicine and clinical program development
- Preclinical disease modeling
Key Technologies
- AAV vector capsid engineering
- In vivo NHP high-throughput screening
- Computational predictive modeling
- Targeted long-read sequencing
News & Updates
Latus launched with state-of-the-art gene therapy development technologies, two lead product candidates, and an initial $54 million in Series A financing.
Coverage of Latus Bio's industry news, interviews, and analysis from various news outlets.
Latus Bio published research on a novel AAV capsid variant for gene therapy targeting Huntington’s and Parkinson’s diseases.
Latus Bio announced a new AAV-Ep+ capsid variant capable of high protein production in the brain.
A publication discussing trends in gene therapy for brain disorders.
Latus Bio presented preclinical data supporting its Huntington’s disease gene therapy.
Latus launched with state-of-the-art gene therapy development technologies, two lead product candidates, and an initial $54 million in Series A financing.
Coverage of Latus Bio's industry news, interviews, and analysis from various news outlets.
Latus Bio published research on a novel AAV capsid variant for gene therapy targeting Huntington’s and Parkinson’s diseases.
Latus Bio announced a new AAV-Ep+ capsid variant capable of high protein production in the brain.
A publication discussing trends in gene therapy for brain disorders.
Latus Bio presented preclinical data supporting its Huntington’s disease gene therapy.